CSL – Credit Suisse rates the stock as Outperform

By Broker News | More Articles by Broker News

A tight market in plasma presents an opportunity in Europe, Credit Suisse notes. The broker suspects the US political environment, where CSL generates 55% of its immunoglobulin revenue, is likely to limit any significant price rises.

However, with prices more than -20% lower in Europe and the rest of the world the broker believes prices are likely to converge. Outperform rating maintained. Target rises to $305 from $249.

Credit Suisse believes the valuation is justified given the strong market position in a niche industry that has robust fundamentals.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $305.00.Current Price is $285.43. Difference: $19.57 – (brackets indicate current price is over target). If CSL meets the Credit Suisse target it will return approximately 6% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →